Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Archive ouverte

Pfisterer, Jacobus | Shannon, Catherine | Baumann, Klaus | Rau, Joern | Harter, Philipp | Joly, Florence | Sehouli, Jalid | Canzler, Ulrich | Schmalfeldt, Barbara | Dean, Andrew | Hein, Alexander | Zeimet, Alain | Hanker, Lars | Petit, Thierry | Marme, Frederik | El-Balat, Ahmed | Glasspool, Rosalind | de Gregorio, Nikolaus | Mahner, Sven | Meniawy, Tarek | Park-Simon, Tjoung-Won | Mouret-Reynier, Marie-Ange | Costan, Cristina | Meier, Werner | Reinthaller, Alexander | Goh, Jeffrey | L'Haridon, Tifenn | Baron Hay, Sally | Kommoss, Stefan | Du Bois, Andreas | Kurtz, Jean-Emmanuel | Ackermann, Sven | Anthuber, Christoph | Aydogdu, Mustafa | Baldauf, Angelika | Bauer, Wolfgang | Behringer, Dirk | Belau, Antje | Bender, Alexandra | Brucker, Cosima | Burges, Alexander | Daabach, Trygve | Denschlag, Dominik | Deryal, Mustafa | Dörfel, Steffen | Ebert, Juliane | Fehm, Tanja | Feidicker, Susanne Maria | Feisel-Schwickardi, Gabriele | Felberbaum, Ricardo | Frank, Matthias | Gebauer, Gerhard | Gerber, Bernd | Gerhardt, Axel | Grafe, Andrea | Griesshammer, Martin | Grischke, Eva-Maria | Gröll, Isolde | Gropp-Meier, Martina | Hager, Dietrich | Hanf, Volker | Hannig, Carla Verena | Hantschmann, Peer | Hauzenberger, Tanja | Herwig, Uwe | Heubner, Martin | Hielscher, Carsten | Hilpert, Felix | Hitschold, Thomas | Hofmann, Manfred | Jackisch, Christian | Janni, Wolfgang | Kiesel, Ludwig | Ko, Yon-Dschun | Koch, Hans-Joachim | Krabisch, Petra | Krieger, Peter | Kubin, Thomas | Kühn, Thorsten | Lampe, Björn | Ledwon, Peter | Lemster, Sabine | Lex, Benno | Liebrich, Clemens | Lorenz, Ralf | Lück, Hans-Joachim | Mallmann, Peter | Meinerz, Wolfgang | Menke, Götz | Möbus, Volker | Muller, Thomas | Müller, Volker | Neunhöffer, Tanja | Ober, Angelika | Oskay-Özcelik, Gülten | Ostertag, Horst | Pölcher, Martin | Rautenberg, Beate | Rein, Daniel | Reiter, Wilhelm | Rempen, Andreas | Runnebaum, Ingo | Schmidt, Marcus | Schnohr, Sabine | Scholz, Heinz | Schröder, Willibald | Simon, Eike | Sperfeld, Antje | Steckkönig, Annette | Strauss, Hans-Georg | Stuth, Ronaldo | Terhaag, Jürgen | Thiel, Falk | Thill, Marc | Tomé, Oliver | Uleer, Christoph | Vogel, Susanne | Voss, Hermann | Weigel, Michael | Winkler, Ulrich | Wischnik, Arthur | Zeiser, Tobias | Zorr, Andreas | Glasspool, Ros | Hudson, Emma | Jones, Rachel | Lafleur, Judith | Marth, Christian | Petru, Edgar | Antill, Yoland | Azer, Mary | Baron-Hay, Sally | Beale, Philip | Begbie, Stephen | Black, Allison | Briscoe, Karen | Harvey, Sandra | Lee, Chee | Matos, Marco | Olesen, Inger | Vasey, Paul | Abadie-Lacourtoisie, Sophie | Arsene, Olivier | Barthier, Sophie | Becuwe-Roemer, Célia | Berton-Rigaud, Dominique | Cappiello-Bataller, Maria | Catala, Stéphanie | del Piano, Francesco | Deplanque, Gaël | Despax, Raymond | Dohollou, Nadine | Garnier-Tixidré, Claire | Grenier, Julien | Guardiola, Emmanuel | Hardy-Bessard, Anne-Claire | Lefeuvre-Plesse, Claudia | Leheurteur, Marianne | Lesoin, Anne | Levache, Charles-Briac | Longo, Raffaele | Lortholary, Alain | Meunier, Jérôme | Raban, Nadia | Romano, Olivier | Vannetzel, Jean-Michel | Zannetti, Alain

Edité par CCSD ; Elsevier -

International audience. State-of-the art therapy for recurrent ovarian cancer suitable for platinum-based re-treatment includes bevacizumab-containing combinations (eg, bevacizumab combined with carboplatin-paclitaxel or carboplatin-gemcitabine) or the most active non-bevacizumab regimen: carboplatin-pegylated liposomal doxorubicin. The aim of this head-to-head trial was to compare a standard bevacizumab-containing regimen versus carboplatin-pegylated liposomal doxorubicin combined with bevacizumab.

Consulter en ligne

Suggestions

Du même auteur

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial

Archive ouverte | Harter, P. | CCSD

International audience. The use of first-line poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is increasing in advanced ovarian cancer. Understanding the efficacy of first subsequent therapy (FST) i...

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Archive ouverte | Geyer, C.E. | CCSD

International audience

Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial

Archive ouverte | Fumet, Jean-David | CCSD

International audience. Background: Following disappointing results with PD-1/PD-L1 inhibitors in ovarian cancer, it is essential to explore other immune targets. The aim of this study is to describe the tumor immun...

Chargement des enrichissements...